TransCode Therapeutics
RNAZ----
TransCode Therapeutics (RNAZ)
TransCode Therapeutics, Inc., a clinical-stage company, develops immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers. The c...
- Open
- --
- High
- --
- Low
- --
- Prev. Close
- --
- Volume
- --
- Turnover
- --
- Avg Price
- --
- Bid/Ask Ratio
- --
- Amplitude
- --
- 52wk High
- --
- Volume Ratio
- --
- Turnover Ratio
- --
TransCode Therapeutics Analyst Rating
View MoreForecast & Rating
Apr 16, 2025Price forecast
$280.005037.61%
Forecast & RatingBuy
1analysts
- Strong buy0.00%
- Buy100.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- PUBT · Jul 20 at 03:17 PM
TransCode Therapeutics holds annual shareholder meeting
- Tip Ranks · Jul 17 at 04:33 PM
TransCode Therapeutics Updates Preferred Stock Ownership Limits
- PUBT · Jul 2 at 03:07 PM
TransCode Therapeutics adjourns annual shareholder meeting to July 20 pending Nasdaq review
- Quartr · Jul 2 at 09:50 AM
RNAZ: Meeting adjourned to July 20, 2026, pending Nasdaq listing review completion
- rttnews · Jul 1 at 10:22 PM
Top Biotech Gainers: CANF Climbs, RGNT Gears Up For Europe Launch, RNAZ, ELTX On Watch
- rttnews · Jun 30 at 09:45 PM
Top Biotech Gainers: ABVX Soars On UC Trial Data, PMN Eyes Alzheimer's Catalyst, TRAX In Focus
